E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
respiratory syncytial virus infection |
|
E.1.1.1 | Medical condition in easily understood language |
respiratory syncytial virus infection |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Study A: The main objective of this non-commercial trial is self-reported symptoms (local and systemic AE's) according to the FDA scorecard and SAE’s. The phase IIb will be initiated based on the overall safety profile, there must be no treatment SAE or AE's as determined by the investigator and DSMB. Study B: The primary objective of this non-commercial trial is RSV infection with lab-confirmed diagnosis.
|
|
E.2.2 | Secondary objectives of the trial |
Study A: Observation of symptoms by a physician will take place for the 10 minutes following administration on the first day of intervention. We will test nasal swab samples for a respiratory panel to exclude the possibility of respiratory pathogen as the cause of symptoms when symptoms are present. Study B: RSV hospitalization*, medically-attended RSV infection, any hospitalization, any non-hospitalized RSV infection, any respiratory disease, non-tested medically attended respiratory tract infection (RTI), RSV negative RTI admission, non-tested RTI admission, use of respiratory medication, otitis media, and wheeze in the first year of life. Incidence and total days of RSV-associated ICU stay, mechanical ventilation and supplemental oxygen. Nasal swabs for co-infections by other respiratory pathogens. Safety data on local and systemic adverse events and severe adverse events. *: Key secondary outcome
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Study A Adult men and women between the ages of 18 and 60 in good health based on relevant medical history.
Study B Healthy preterm infants with gestational age between 32 and 35 weeks and less than 6 months of age at the onset of the RSV season. Children must have a least one sibling. Only children of parents who master the Dutch language are included.
|
|
E.4 | Principal exclusion criteria |
Study A Adults with a nasal cold or obstructions in the nasal cavity that could interfere with administration of the study vaccine are excluded. History of any respiratory symptoms or clinically significant infectious disease within 4 weeks prior to drug administration or immunocompromised subjects are excluded from the study. Final, nasal surgery prior to or during the trial is an exclusion criterion.
Study B Children with a known cardiac anomaly, Down syndrome or other serious congenital disorders and children who received surfactant treatment are excluded from the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Any RSV infection with laboratory-confirmed RSV. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Follow up for RSV infection will occur only during the first RSV season from initiation of treatment through the end of April. |
|
E.5.2 | Secondary end point(s) |
RSV hospitalization*, medically-attended RSV infection, any hospitalization, any non-hospitalized RSV infection, any respiratory disease, non-tested medically attended respiratory tract infection (RTI), RSV negative RTI admission, non-tested RTI admission, use of respiratory medication, otitis media, and wheeze in the first year of life. Incidence and total days of RSV-associated ICU stay, mechanical ventilation and supplemental oxygen. Nasal swabs for co-infections by other respiratory pathogens. Safety data on local and systemic adverse events and severe adverse events. *: Key secondary outcome
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Follow up for RSV hospitalization, medically-attended RSV infection, any hospitalization, any non-hospitalized RSV infection, any respiratory disease, non-tested medically attended respiratory tract infection (RTI), RSV negative RTI admission, non-tested RTI admission, otitis media, and days ICU admission/ mechanical ventilation/supplemental oxygen will occur only during the first RSV season from initiation of treatment through the end of April. Follow-up for wheeze and respiratory medication use will occur through the first year of life. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial will end once the inclusion goal of n=348 has been reached. If the sample size is not reached by the end of the second RSV season a futility analysis will be performed with a conditional power of at least 10% for success to determine whether a third season of enrollement will be performed. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |